Urinary Incontinence: Reproductive/Hormonal Risk Factors (RRISK3)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00836979|
Recruitment Status : Completed
First Posted : February 4, 2009
Last Update Posted : April 7, 2015
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||2161 participants|
|Official Title:||Urinary Incontinence: Reproductive/Hormonal Risk Factors III|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||December 2012|
- Race/Ethnicity [ Time Frame: up to 48 months ]To investigate the two- to three-fold greater prevalence of stress UI in White women, compared to Black and Asian women which we previously reported we will (a) create and compare risk factor models of UI for each racial/ethnic group (White, Black, Hispanic, Asian); b) determine the extent to which racial differences can be explained by differences in newly measured exposures and genetic polymorphisms in addition to previously identified risk factors. To increase study power, we will enroll an additional 450 women (150 Black, 150 Asian and 150 Hispanic) into the RRRISK cohort.
- Hormones [ Time Frame: up to 48 months ]To further characterize the association between hormones and UI and to determine if phytoestrogens are a risk factor for UI we will (a) use pharmacy records, supplemented by self-report, to ascertain the type, dose, duration and delivery for estrogens and for selective estrogen reuptake inhibitors (SERMs) and test their association with UI; (b) estimate phytoestrogen exposure from self-reported intake of key foods and botanicals and test the association with UI using multivariate analysis.
- Gene Polymorphisms [ Time Frame: up to 48 months ]To test the association between estrogen receptor gene polymorphisms and UI we will use banked serum samples from the RRISK cohort to assay for polymorphisms of the two estrogen receptor genes (ESR1 and ESR2) and determine their associations with urinary incontinence.
- New UI and Progressive UI [ Time Frame: up to 48 months ]We will analyze approximately 20,000 person-years of observational data using multiple regression techniques to (a) determine rates of new UI and changes in UI frequency/severity (including remission) and (b) identify risk factors for new UI and change in UI severity.
- Pre-Diabetes [ Time Frame: up to 48 months ]To investigate the association between pre-diabetes and increased risk of UI recently reported by members of our group we will (a) examine the cross-sectional association between pre-diabetes and UI, controlling for multiple other variables including body mass, waist circumference, inflammatory markers, and coronary heart disease; (b) conduct in-person interviews, measure physical parameters, and obtain blood tests on the approximately 400 women in the current study cohort with pre-diabetes. This additional prospective data on pre-diabetic women will allow us to characterize the natural history of the association between pre-diabetes and progression or new onset of UI.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00836979
|United States, California|
|Kaiser Division of Research|
|Oakland, California, United States, 94612|
|Principal Investigator:||Stephen K Van Den Eeden, PhD||Kaiser Division of Research|
|Principal Investigator:||Jeanette Brown, MD||UCSF/Mr. Zion WHCRC|
|Principal Investigator:||David Thom, MD||UCSF/Family and Community Medicine|